Navigating through the PD-1/PDL-1 Landscape: A Systematic Review and Meta-Analysis of Clinical Outcomes in Hepatocellular Carcinoma and Their Influence on Immunotherapy and Tumor Microenvironment

Navigating through the PD-1/PDL-1 Landscape: A Systematic Review and Meta-Analysis of Clinical Outcomes in Hepatocellular Carcinoma and Their Influence on Immunotherapy and Tumor Microenvironment

This systematic review aimed to assess the prognostic significance of programmed cell death-ligand 1 (PDL-1) and programmed cell death protein 1 (PD-1) in hepatocellular carcinoma (HCC). Medline, EMBASE, and Cochrane Library database searches were conducted, revealing nine relevant cohort studies (s...

Full description

Bibliographic Details
Main Authors:	Muhammad Joan Ailia, Jeong Heo, So Young Yoo
Format:	Article
Language:	English
Published:	MDPI AG 2023-03-01
Series:	International Journal of Molecular Sciences
Subjects:	hepatocellular carcinoma (HCC) immunotherapy immune checkpoint inhibitors (ICIs) programmed cell death protein 1 (PD-1) programmed cell death-ligand 1 (PDL-1) tumor microenvironment (TME)
Online Access:	https://www.mdpi.com/1422-0067/24/7/6495

Similar Items

Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
by: Fereshteh Ameli, et al.
Published: (2022-08-01)

A comparative study to assess the increased expression of programmed cell death-1 (PD1) and programmed cell death- ligand-1 (PDL1) in oral potentially malignant disorders and oral squamous cell carcinoma
by: Sonalika Srivastava, et al.
Published: (2023-01-01)

Engineering of a Bispecific Nanofitin with Immune Checkpoint Inhibitory Activity Conditioned by the Cross-Arm Binding to EGFR and PDL1
by: Perrine Jacquot, et al.
Published: (2023-03-01)

Expression of Programmed Cell Death-1 (PD-1) and Its Ligand (PD-L1) in Breast Cancers and Its Association with Clinicopathological Parameters
by: Anoushika Mehan, et al.
Published: (2022-03-01)

Downregulation of Immunosuppressive Molecules, PD-1 and PD-L1 but not PD-L2, in the Patients with Multiple Sclerosis
by: Mohammad Reza Javan, et al.
Published: (2016-08-01)

Expression of PD-1 and PD-L1 in Breast Carcinoma: Research Protocol for a Cohort Study
by: Shreya Ghosh, et al.
Published: (2023-11-01)

GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression
by: Young Wha Koh, et al.
Published: (2017-03-01)

Efficacy and Safety of PD-1/PD-L1 Inhibitor as Single-Agent Immunotherapy in Endometrial Cancer: A Systematic Review and Meta-Analysis
by: Mohd Nazzary Mamat @ Yusof, et al.
Published: (2023-08-01)

Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis
by: Feng Xian, et al.
Published: (2023-04-01)

The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade
by: Sajad Najafi, et al.
Published: (2023-05-01)

Analysis of the Correlation between Molecular Structural Differences of PD-1/PD-L1 Inhibitors and Adverse Events
by: Tongji XIE, et al.
Published: (2020-07-01)

PD-1/PD-L1 Correlates With the Efficacy of the Treatment of Concurrent Chemoradiotherapy in Cervical Cancer
by: Hanqun Zhang, et al.
Published: (2022-05-01)

Percentages of PD-1+CD4+T cells and PD-L1+DCs are increased and sPD-1 level is elevated in patients with immune thrombocytopenia
by: Yingying Wang, et al.
Published: (2018-04-01)

Advances in Promoting the Efficacy of Chimeric Antigen Receptor T Cells in the Treatment of Hepatocellular Carcinoma
by: Jie Shen, et al.
Published: (2022-10-01)

Peripheral blood T lymphocytes are downregulated by the PD-1/PD-L1 axis in advanced gastric cancer
by: Witold Zgodzinski, et al.
Published: (2018-04-01)

The significance of PD-1/PD-L1 imbalance in ulcerative colitis
by: Wei Shi, et al.
Published: (2023-05-01)

Comparison of Immune Checkpoint Molecules <i>PD-1</i> and <i>PD-L1</i> in Paired Primary and Recurrent Glioma: Increasing Trend When Recurrence
by: Wei Yu, et al.
Published: (2022-02-01)

Computational Approaches Drive Developments in Immune-Oncology Therapies for PD-1/PD-L1 Immune Checkpoint Inhibitors
by: Patrícia S. Sobral, et al.
Published: (2023-03-01)

The relationship between the PD-1/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance
by: Feng YC, et al.
Published: (2018-01-01)

PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients
by: Federica Costa, et al.
Published: (2021-01-01)

Mechanisms of CD8+ T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1
by: Keywan Mortaezaee, et al.
Published: (2023-07-01)

Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
by: Qiang Liu, et al.
Published: (2017-01-01)

Truncated PD1 Engineered Gas‐Producing Extracellular Vesicles for Ultrasound Imaging and Subsequent Degradation of PDL1 in Tumor Cells
by: Siyan Zhang, et al.
Published: (2024-03-01)

Lanosterol synthase deficiency promotes tumor progression by orchestrating PDL1‐dependent tumor immunosuppressive microenvironment
by: Yuan Gao, et al.
Published: (2024-04-01)

Nivolumab Enhances In Vitro Effector Functions of PD-1+ T-Lymphocytes and Leishmania-Infected Human Myeloid Cells in a Host Cell-Dependent Manner
by: Christodoulos Filippis, et al.
Published: (2017-12-01)

Progress of research on PD-1/PD-L1 in leukemia
by: Huizhen Cao, et al.
Published: (2023-09-01)

Anti-programmed death ligand 1 (PD-L1) inhibitors in metastatic gastric cancer
by: Jang Ho Cho, et al.
Published: (2017-12-01)

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
by: Maureen L. Drakes, et al.
Published: (2018-05-01)

The Expression Levels and Concentrations of PD-1 and PD-L1 Proteins in Septic Patients: A Systematic Review
by: Mutiara Indah Sari, et al.
Published: (2022-08-01)

PD-1/PD-L1 Axis as a Potential Therapeutic Target for Multiple Sclerosis: A T Cell Perspective
by: HaiXia Li, et al.
Published: (2021-07-01)

Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives
by: Ran X, et al.
Published: (2017-07-01)

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
by: Luisa Chocarro de Erauso, et al.
Published: (2020-04-01)

Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations
by: Jiqiao Yang, et al.
Published: (2019-07-01)

Sequential Blockade of PD-1 and PD-L1 Causes Fulminant Cardiotoxicity—From Case Report to Mouse Model Validation
by: Shin-Yi Liu, et al.
Published: (2019-04-01)

Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy
by: Qin Qiu, et al.
Published: (2021-01-01)

Emerging role of the immunotherapy in treatment of breast cancer
by: Nagwa Abd El-Sadek Ahmed*, et al.
Published: (2021-08-01)

PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer
by: Jong-Mu Sun
Published: (2017-03-01)

Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations
by: Xiang Chen, et al.
Published: (2024-02-01)

Neoadjuvant PD-1 Blockade in Non-Small Cell Lung Cancer: Current perspectives and Moving Forward
by: Shinada K, et al.
Published: (2023-02-01)

Protective effects of blocking PD-1 pathway on retinal ganglion cells in a mouse model of chronic ocular hypertension
by: Siqi Sheng, et al.
Published: (2023-01-01)